Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M–Positive Lung Cancer and Acquired Resistance to Osimertinib

R. Oxnard, Geoffrey; Hu, Yuebi; F. Mileham, Kathryn; Husain, Hatim; B. Costa, Daniel; Tracy, Philip; Feeney, Nora; M. Sholl, Lynette; E. Dahlberg, Suzanne; J. Redig, Amanda; J. Kwiatkowski, David; S. Rabin, Michael; P. Paweletz, Cloud; S. Thress, Kenneth; A. Jänne, Pasi

doi:10.1001/jamaoncol.2018.2969

Public

Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M–Positive Lung Cancer and Acquired Resistance to Osimertinib

Published in JAMA Oncology • Aug 2, 2018

Authors:

Geoffrey R. Oxnard

Yuebi Hu

Kathryn F. Mileham

Abstract

Importance: Osimertinib mesylate is used globally to treat EGFR-mutant non-small cell lung cancer (NSCLC) with tyrosine kinase inhibitor resistance mediated by the EGFR T790M mutation. Acquired resistance to osimertinib is a growing clinical challenge that is poorly understood. Objective: To underst...

Subject

Osimertinib

T790M

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!